Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self

Immunological Reviews

Volumn 214, Issue 1, 2006, Pages 202-218

  Ruggeri, Loredana ^a   Aversa, Franco ^a   Martelli, Massimo F ^a   Velardi, Andrea ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Allogeneic hematopoietic transplantation; Alloreactivity; Cancer immunotherapy; Graft versus host disease; Graft versus leukemia effect; Leukemia; Natural killer cells

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE ANTIBODY; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ASPERGILLOSIS; BACTERIAL INFECTION; BONE MARROW TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANDIDIASIS; CELLULAR IMMUNITY; CHROMOSOME 12; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; EOSINOPHILIA; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; MYELODYSPLASIA; MYELOPROLIFERATIVE DISORDER; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; ISOANTIGENS; KILLER CELLS, NATURAL; TRANSPLANTATION, HOMOLOGOUS;

EID: 33750726384     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/j.1600-065X.2006.00455.x     Document Type: Review

References (130)

1. Blume KG, Forman SJ, Appelbaum FR. Hematopoietic Cell Transplantation, 3rd edn. Malden, MA: Blackwell Science, 2004.
2. Atkinson K, Fibbe W, Champlin R, Ljungman L, Ritz J, Brenner M. Clinical Bone Marrow and Blood Stem Cell Transplantation. 3rd edn. Cambridge: Cambridge University Press, 2004.
3. Copelan EA. Hematopoietic stem cell transplantation. N Engl J Med 2006;354:1813-1826.
4. Kolb HJ, Schimd A, Barret J, Schendel DJ. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004;103:767-776.
5. Ferrara JLM, Cooke KR, Deeg J. Graft vs. Host Disease. 3rd edn. New York: Marcel Dekker, 2004.
6. Goulmy E, et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J Med 1996;334:281-285.
7. Wang W, et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 1995;269:1588-1590.
8. Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol Rev 1997;157:125-140.
9. Mutis T, Goulmy E. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin Hematol 2002;39:23-31.
10. Spierings E, Goulmy E. Expanding the immunotherapeutic potential of minor histocompatibility antigens. J Clin Invest 2005;115:3397-3400.
11. Szydlo R, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA identical siblings. J Clin Oncol 1997;15:1767-1777.
12. Petersdorf E, et al. Genomics of unrelated-donor hematopoietic-cell transplantation. Curr Opin Immunol 2001;13:582-589.
13. Petersdorf EW, et al. Major histocompatibility complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 2001;345:1794-1800.
14. Petersdorf EW, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998;92:3515-3520.
15. Sasazuki T, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med 1998;339:1177-1185.
16. Hurley CK, et al. National Marrow Donor Program HLA-matching guidelines for unrelated marrow transplant. Biol Blood Marrow Transplant 2003;10:610-615.
17. Saarinen-Pihkala UM, et al. No disadvantages in outcome using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol 2001;19:3406-3414.
18. La Nasa G, et al. Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes. Blood 2002;99:4350-4356.
19. Eapen M, et al. Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantation for acute leukemia in children younger than 18 months. J Clin Oncol 2006;24:145-151.
20. Gluckman E, et al. Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-1178.
21. Wagner JE, et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002;100:1611-1618
22. Laughlin MJ, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med 2004;351:2265-2275.
23. Rocha V, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. New Engl J Med 2004;351:2276-2285.
24. Barker JN, et al. Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy. Blood 2005;105:1343-1347.
25. Cudkowicz G, Bennett M. Peculiar immunobiology of bone-marrow allografts. II. Rejection of parental grafts by resistant F1 hybrid mice. J Exp Med 1972;135:1028-1036.
26. Murphy WJ, Kumar V, Bennett, M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J Exp Med 1987;165:1212-1217.
27. Yu YY, George T, Dorfman JR, Roland J, Kumar V, Bennett M. The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T cell blasts. Immunity 1996;4:67-76.
28. Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005;6:938-945.
29. Ruggeri L, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999;94:333-339.
30. Ruggeri L, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-2100.
31. Shlomchik WD, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999;285:412-415.
32. Ruggeri L, Perruccio K, Montagnoli C, Romani L, Velardi A. NK cell conditioning to T cell-replete mismatched BMT confers immediate responsiveness to infectious challenges. Bone Marrow Transplant 2004;33:S18.
33. Reisner Y, et al. Transplantation for severe combined immunodeficiency with HLA-A, B, D, DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red cells. Blood 1983;61:341-348.
34. Fischer A, et al. European experience of bone-marrow transplantation for severe combined immunodeficiency. Lancet 1990;336:850-854.
35. Buckley RH, et al. Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. New Engl J Med 1999;340:508-516.
36. Bachar-Lustig E, Rachamim N, Li HW, Lan F, Reisner Y. Megadose of T-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice. Nat Med 1995;1:1268-1273.
37. Aversa F, et al. Successful engraftment of Tdepleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-3955.
38. Aversa F, et al. Treatment of high risk acute leukaemia with T-depleted stem cells from related donors with one fully mismatched HLA haplotype. New Engl J Med 1998;339:1186-1193.
39. Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli MF. Haploidentical stem cell transplantation in leukemia. Blood Rev 2001;15:111-119.
40. Martelli MF, Aversa F, Velardi A, Tabilio A, Reisner Y. Transplants across human leukocyte antigen barriers. Semin Hematol 2002;39:48-56.
41. Anasetti C, Velardi A. Hematopoietic cell transplantation from HLA partially matched related donors. In: Blume KG, Forman SJ, Appelbaum FR, eds. Hematopoietic Cell Transplantation, 3rd edn. Malden, MA: Blackwell Science, 2004:1116-1131.
42. Aversa F, et al. Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447-3454.
43. Kärre K. A perfect mismatch. Science 2002;295:2029-2031.
44. Velardi A, Ruggeri L, Moretta A, Moretta L. NK-cells: a lesson from mismatched haematopoietic transplantation. Trends Immunol 2002;23:438-444.
45. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft versus leukemia effect. Blood 2002;100:1935-1947.
46. Caligiuri MA, Velardi A, Scheinberg DA, Borrello IM. Immunotherapeutic approaches for haematological malignancies. In: Broudy VC, Berliner N, Larson RA, Leurg LL eds. Hematology 2004, ASH Education Program Book. Washington: American Society of Hematology, 2004:337-353.
47. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of alloreactive natural killer cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17:211-217.
48. Kärre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-2 deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986;319:675-678.
49. Ljunggren HG, Kärre K. In search of the 'missing self'. MHC molecules and NK cell recognition. Immunol Today 1990;11:237-244.
50. Moretta L, et al. Allorecognition by NK cells: nonself or no self? Immunol Today 1992;13:300-306.
51. Ciccone E, Pende D, Viale O, Hoglund P, Ohlen C, Karre K. Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J Exp Med 1992;175:709-718.
52. Colonna M, Brooks EG, Falco M, Ferrara GB, Strominger JL. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 1993;260:1121-1124.
53. Valiante NM, et al. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 1997;7:739-751.
54. Moretta A, et al. Identification of four subsets of human CD3-CD16+ NK cells by the expression of clonally distributed functional surface molecules. Correlation between subset assignment of NK clones and ability to mediate specific alloantigen recognition. J Exp Med 1990;172:1589-1598.
55. Moretta A, et al. P58 molecules as putative receptors for MHC class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J Exp Med 1993;178:597-604.
56. Colonna M, Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 1995;268:405-408.
57. Uhrberg M, et al. Human diversity in killer cell inhibitory receptor genes. Immunity 1997;7:753-760.
58. Long EO. Regulation of immune responses through inhibitory receptors. Annu Rev Immunol 1999;17:875-904.
59. Vilches C, Parham P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Ann Rev Immunol 2002;20:217-251.
60. Moretta L, Moretta A. Killer immunoglobulin-like receptors. Curr Opin Immunol 2004;16:626-633.
61. Lopez-Botet M, et al. Structure and function of the CD94 C-type lectin receptor complex involved in the recognition of HLA class I molecules. Immunol Rev 1997;155:165-174.
62. Braud VM, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795-799.
63. Moretta A, Biassoni R, Bottino C, Mingari MC, Moretta L. Natural cytotoxicity receptors that trigger human NK cell-mediated cytolysis. Immunol Today 2000;21:228-234.
64. Moretta A, et al. Activating receptors and co-receptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
65. Lanier LL. On guard - activating NK cell receptors. Nat Immunol 2001;2:23-27.
66. Lanier LL. Face off - the interplay between activating and inhibitory immune receptors. Curr Opin Immunol 2001;13:326-331.
67. Moretta L, Moretta A. Unravelling natural killer cell function: triggering and inhibitory human NK receptors. EMBO J 2004;23:255-259.
68. Moretta L, Bottino C, Pende D, Vitale M, Mingari MC, Moretta A. Different checkpoints in human NK cell activation. Trends Immunol 2004;25:670-676.
69. Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-274.
70. Wu J, et al. An activating immunoreceptor complex formed by NKG2D and DAP10. Science 1999;285:730-732.
71. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH. The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 2002;17:19-29.
72. Bauer S, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
73. Cosman D, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001;14:123-133.
74. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH. Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 2000;1:119-126.
75. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001;413:165-171.
76. Cerwenka A, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 2000;12:721-727.
77. Groh V, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-6884.
78. Sutherland CL, et al. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. J Immunol 2002;168:671-679.
79. Kubin M, et al. ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells. Eur J Immunol 2001;31:1428-1437.
80. Pende D, et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 2002;62:6178-6186.
81. Sivori S, et al. P46, a novel natural killer cell specific surface molecule which mediates cell activation. J Exp Med 1997;186:1129-1136.
82. Vitale M, et al. NKp44, a novel triggering surface molecule specifically expressed by activated natural killer cells is involved in non-MHC restricted tumor cell lysis. J Exp Med 1998;187:2065-2072.
83. Pessino A, et al. Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med 1999;188:953-960.
84. Cantoni C, et al. NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily. J Exp Med 1999;189:787-796.
85. Pende D, et al. Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells. J Exp Med 1999;190:1505-1516.
86. Sivori S, et al. NKp46 is the major triggering receptor involved in the natural cytotoxicity of fresh or cultured human NK cells. Correlation between surface density of NKp46 and natural cytotoxicity against autologous, allogeneic or xenogeneic target cells. Eur J Immunol 1999;29:1656-1666.
87. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med 2002;195:343-351.
88. Moretta A, et al. Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells. J Exp Med 1995;182:875-884.
89. Biassoni R, et al. Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules. Eur J Immunol 1997;27:3095-3099.
90. Vales-Gomez M, Reyburn HT, Erskine RA Strominger JL. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci USA 1998;95:14326-14331.
91. Winter CC, Gumperz JE, Parham P, Long EO, Wagtmann N. Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J Immunol 1998;161:571-577.
92. Parham P. MHC class I molecules and KIRs in human history, health and survival. Nat Rev Immunol 2005;5:201-214.
93. Saulquin X, Gastinel LN, Vivier E. Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j). J Exp Med 2004;197:933-938.
94. Andrew Stewart C, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci USA 2005;102:13224-13229.
95. Shilling HG, et al. Genetic control of human NK cell repertoire. J Immunol 2002;169:239-247.
96. Yawata M, Yawata N, Draghi M, Little AM, Parteniou F, Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006;203:633-645.
97. Velardi A, Moretta A. Role of natural killer cell alloreactivity in hematopoietic stem cell transplantation. In: Atkinson K, Fibbe W, Champlin R, Ljungman L, Ritz J, Brenner M, eds. Clinical Bone Marrow and Blood Stem Cell Transplantation, 3rd edn. Cambridge: Cambridge University Press, 2004:247-261.
98. Mackall CL, Hakim FT, Velardi A. The immune system in graft-vs.-host disease: target and effector organ. In: Ferrara JLM, Cooke KR, Deeg J, eds. Graft vs. Host Disease, 3rd edn. New York: Marcel Dekker, 2004:195-227.
99. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005;106:376-383.
100. Igarashi T, et al. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 2004;104:170-177.
101. Leung W, et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004;172:644-650.
102. Ruggeri L, Mancusi A, Capanni M, Martelli MF, Velardi A. Exploitation of alloreactive natural killer cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005;17:211-217.
103. Pando MJ, et al. The protein made from a common allele of KIR3DL1 (3DL*004) is poorly expressed at cell surfaces due to substitution at position 86 in Ig domain 0 and 182 in Ig domain 1. J Immunol 2003;171:6640-6647.
104. Carr WH, Pando MJ, Parham P. KIR3DL1 polymorphisms that affect NK cell inhibition by HLA-Bw4 ligand. J Immunol 2005;175:5222-5229.
105. Davies SM, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002;100:3825-3827.
106. Giebel S, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003;102:814-819.
107. Lowe EJ, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003;123:323-326.
108. Morishima Y, Yabe T, Inoko H. Clinical significance of killer Ig-like receptor (KIR) on acute GvHD, rejection and leukemia relapse in patients transplanted non-T cell depleted marrow from unrelated donors; roles of inhibitory KIR epitope matching and activating KIR genotype. Blood 2003;102:526a.
109. Elmaagacli AH, Ottinger, HKoldehoff M Reduced risk of molecular and haematological relapse in patients with CML after KIR-mismatched hematopoietic stem cell transplantation. Bone Marrow Transplant 2004;33:S59.
110. Bornhauser M, Schwerdtfeger R, Martin H, Frank KH, Theuser C, Ehninger G. Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors. Blood 2004;103:2860-2861.
111. Beelen DW, et al. Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood 2005;105:2594-2600.
112. Shilling HG, McQueen KL, Cheng NW, Shizuru JA, Negrin RS, Parham P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003;101:3730-3740.
113. Cooley S, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005;106:4370-4376.
114. Hsu KC, et al. Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005;105:4878-4884.
115. Hsu KC, Dupont B. Natural killer cell receptors: regulating innate immune responses to hematologic malignancies. Semin Hematol 2005;42:91-103.
116. Salcedo M, Andersson M, Lemieux S, Van Kaer L, Chambers BJ, Ljunggren HG. Fine tuning of natural killer cell specificity and maintenance of self tolerance in MHC class I-deficient mice. Eur J Immunol 1998;28:1315-1321.
117. Johansson MH, Bieberich C, Jay G, Karre K, Hoglund P. Natural killer cell tolerance in mice with mosaic expression of histocompatibility complex class I transgene. J Exp Med 1997;186:353-364.
118. Raulet DH, Vance RE, McMahon CW. Regulation of the natural killer cell receptor repertoire. Annu Rev Immunol 2001;19:291-230.
119. Raulet DH. Interplay of natural killer cells and their receptors with the adaptive immune response. Nat Immunol 2004;5:996-1002.
120. Fernandez NC, Treiner E, Vance RE, Jamieson AM, Lamieux S, Raulet DH. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 2005;105:4416-4423.
121. Kim S, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 2005;436:709-713.
122. Verheyden S, Schots R, Duquet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation. Leukemia 2005;19:1446-1451.
123. De Santis D, et al. Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants. Tissue Antigens 2005;65:519-528.
124. Cook M, et al. Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T cell replete stem cell transplantation. Blood 2006;107:1230-1232.
125. Gagne K, et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002;63:271-280.
126. Sun JY, et al. Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML. Bone Marrow Transplant 2005;36:525-530.
127. Bishara A, et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004;63:204-221.
128. Miller JS, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in cancer patients. Blood 2005;105:3051-3057.
129. Dudley ME, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-854.
130. Cooper MA, et al. In vivo evidence for a dependence on interleukin 15 for survival of natural killer cells. Blood 2002;100:3633-3638.